Investor Relations

Our framework for driving growth and creating shareholder value = FOCUS on the right things.

1. Focus on new applications for our platform technologies.

2. Focus on the launch stage where we are most skilled and experienced.

3. Focus on gaining patents on pioneering technologies.

4. Focus on developing research collaborations with top tier institutions and individuals.

5. Focus on gaining opinion leader endorsements.

6. Focus on gaining positive press and trade show exposure.

7. Focus on gathering positive supporting data.

8. After first-in-man data is received on organ regeneration and recovery technologies seek a

strategic partner (or 10,000 subscribers for Regenerative Economy innovations)

CalXStars Memorandum

2017 Portfolio of Startups

Orthodonticell Pre-Money Valuation

Master Advisor and Employee Agreements

9. Develop and nurture an innovation culture. Rapid prototyping. Try a lot of stuff and keep

what works. Constant experimentation. Do. Try, Fix, Try again.

10. Use profits from sales of quick to market Regenerative Economy products to fund antidilutive

development of longer to market Regenerative MedTech products and to cover

overhead.

11. Minimize dilution by keeping overhead low. Focus spending on patents, product, people,

positive press, opinion leader endorsements and data; not on overhead. Do more with less.

Bootstrap even when we do not have to bootstrap.

12. Cross fertilize learning between organ specific applications of core platform technologies

= organ regeneration and recovery.

Asli Gozoren

Director of Investor Relations
Leonhardt’s Launchpads by Cal-X
Stars Business Accelerator, Inc.
Second Heart Assist, inc.
OrthodontiCell

“Our accelerator focuses on launching organ regeneration and recovery startups based on common core patented platform technologies. We operate like a tree nursery that develops proprietary seeds. We grow those seeds into small plants in pots and then sell them to strategic partners that grow them into full trees in a full orchard and harvests, markets and sells their fruit. We are not in the tree business, we are not in the orchard business, we are not in the fruit business. We realize our core strength is in inventing and patenting pioneering breakthrough technologies and getting them launched quickly with positive supporting data and key opinion leader endorsements. We believe we can do this in our areas of focus better than anyone else, faster and with less cost. It is this intense focus on what we do best that I believe is our greatest strength.”

Background & Experience

Asli has over 20 years of professional experience working in global corporations such as Grant Thornton, Canadian Imperial Bank of Commerce (CIBC), Fidelity Investments, and global angel investment firm Keiretsu Forum.

Her expertise includes corporate development roles particularly in leading strategic partnerships, managing clients through the entire mergers and acquisitions process in parallel with conducting thorough due diligence, active business development, and fundraising / advisory services to growing businesses ranging across various industries.

Among Asli’s accomplishments are establishing and leading the Corporate Finance / M&A division of consulting firm Grant Thornton International in Istanbul, establishing and growing the largest global angel investment firm to become the leading early stage investment venture within the MENAT region and successfully leading its key global initiatives to increase cross border portfolio syndications. She is also leading the West Coast sales initiatives for a global mergers and acquisitions / joint ventures platform, Headwayz.

Asli is a graduate from Northeastern University in Boston with an International Business and Management degree and lives in San Francisco.

We offer two opportunities with us:

Invest in our innovation & startup accelerator Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc. and own a piece of all 30 startups in our portfolio under 506(c) SEC rules – limited to accredited investors only, permits general solicitation. Company must use reasonable means to verify investor’s accredited status usually with a 3^rd-party reference.

Invest directly in any of our startups that have matured to a level where they have been spun out of the accelerator into a stand-alone C corporation under 506(b) rules. Does not allow general solicitation. Allows up to 35 non-accredited investors. Accredited status is self-verified by investor.

For a limited time we are offering a 2:1 incentive to early stage investors in our innovation & startup accelerator Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc. By example, if you invest $30,000 you receive a $30,000 value common-stock certificate in Cal-X Stars Business Accelerator, Inc. (which gives you partial ownership in all 30 startups) and you get a warrant to acquire $30,000 value of unit shares of startups within the accelerator. You have until Dec. 31st of the year you invested to decide your allocation. You can apply all $30,000 value of warrants to one startup such as HairCell or you can split as little as $1000 per startup in all 30 startups. If you do not let us know by Dec. 31st we will make that allocation split for you by splitting your money into $1,000 amounts (with any excess going into the last amount) and randomly investing your money into the startups, subject to the following restriction regarding startups that have converted from the LTP stage.

Note – All startups in our accelerator start as Licensable Technology Platforms (LTP’s) and are only converted to be stand-alone C corporations once they have matured enough to be financially stable on their own. As an LTP they do not have their own bank account, tax return, accountant, CEO or board of directors. This is all handled by the accelerator on their behalf until they are spun out. If an LTP converts to a C corporation then in order to participate in the 2:1 early stage investor-incentive plan the allocation into the C corporation requires a 2nd approval by that corporation’s board of directors before the allocation is accepted.

Bruce Methven

Corporate Securities Attorney
Advisor to Board of Directors, Leonhardt’s Launchpads
by Cal-X Stars Business Accelerator, Inc.

Background & Experience

Owner Methven & Associates Professional Corporation
Admitted to the State Bar of California 1980
Author Book – Raising Money Legally: A Practical Guide to Raising Capital 2012/13 by Bruce Methven
PRACTICE AREAS
Corporations and partnerships, securities offerings, leases, contracts, intellectual property, international business, real estate, litigation
AFFILIATIONS
• Alameda County Bar Association
• Bar Association of Los Angeles
• American Bar Association
• American Arbitration Association
• EFF Electronic Frontier Foundation
• CPSR Computer Professionals for Social Responsibility
• ERN Entrepreneurs Resource Network-founder and president
• Founder and Former Chair – Alameda County Bar Association,
• Intellectual Property and Computer Law Committee
• Former Chair – Intellectual Property Committee, BAMTA
• Former President – High Technology Entrepreneurial Council
• Former Director – MDG.org Multimedia Development Group, Legal Counsel
• Former Director – Junior Achievement, Legal Counsel
EDUCATION
• Boalt Hall School of Law, University of California at Berkeley
• BA, University of California at Berkeley
• Two years of undergraduate work at Massachusetts Institute of Technology MIT Cambridge, MA
He founded and for three years chaired the Intellectual Property and Computer Law Committee for the Alameda County Bar Association. Previously he was the President of the Entrepreneurs Resource Network.

Risks & Warnings

Investment in our innovation & startup accelerators(s) and our startups is deemed extremely risky. This type of investment is not suitable to inexperienced investors. This type of investment is not suitable for nest-egg savings. We are attempting technological achievements that have never been accomplished before by anyone else. We are operating with nowhere near the amount of capital and personnel resources deemed normally necessary to develop and bring to market these products. All of our agreements in all directions are subject to conditions, often financial, which may not be met. Although we attempt to ensure all information is accurate and up to date across over 10,000 pages on over 40 web sites it is highly likely there are mistakes and outdated information. By entrepreneurial inclination we accentuate the positive in our news developments and reduce attention to the negatives. Our team has failed in the past to have full commercial success with products and return on investment to investors where we thought commercial success was possible and even probable. By experience with new early stage innovations of our 30 startups we realistically can expect most to fail to reach their set goals and at best only a few of them, if any, to reach great success.

1. We are operating with far fewer funds and a smaller staff than all the competitors we know of in the fields we operate in today. We may not have sufficient capital or personnel resources to bring our products through first-in-man studies as is our goal. We have nowhere near the capital to bring any of our products all the way to market through all phases of clinical trials normally required.

2. Our patents and patent options + licenses are all subject to conditions, maintenance fees and other requirements that may not be met due to cash flow difficulties.

3. We may be sued for patent infringement by other patent holders.

4. Our strategic partnerships and research agreements are all subject to conditions and requirements which may not be met.

5. Our technologies are not proven to be either safe or effective and are all early stage in nature.

6. The disease states we are addressing, such as heart failure, have a history of failed attempts at new technologic breakthroughs.

7. A disproportionate to normal substantial portion of our capital goes to breakfasts, lunches and dinners with advisors, investigators, potential and existing investors, researchers, potential and existing employees and board members and potential strategic partners.

8. Howard J. Leonhardt has at this time complete voting majority of shares for nearly all startups in our accelerator(s) and the accelerator itself. In many cases he has special voting rights for him to maintain his control of ownership through an exit sale.

9. Howard J. Leonhardt and our entire core staff is spread thin across not only the 30 startups in our accelerator but other endeavors.

10. Most of our management team and board have other jobs other than working just for us.

11. No stem-cell-based organ-regeneration startup that we know of has become a commercial success yet.

12. The goal to fully regenerate damaged or diseased organs back to full health and function has not been accomplished by anyone ever before.

13. We may be sued for misleading investors although we attempt not do so.

14. We may be sued for injuring patents although we attempt not to do so.

15. We are entering industries with high regulatory obstacles and may not meet all those obligations to remain in compliance considering in particular our small staff and low amount of funds.

16. We generally utilize substantially less legal, accounting and regulatory outside help than most counterparts in our industry. This puts us in position of greater risk.

17. We generally purchase substantially less insurance coverage than most counterparts in our industry.

18. Our labs and research may be in violation of environmental regulations.

19. Our labs and research may be in violation of animal ethics regulations.

20. We do not have control of our manufacturing quality or continuity of supply since we work 100% with external manufacturers.

21. Competitors with more resources may be able to copy our products and bring them to market more quickly.

ALL Cal-X Stars Business Accelerator, Inc. investors must verify their accredited status via Crowdentials, EarlyIQ or Healthiosxchange

Leonhardt Pitch Deck

Click to Download

Cal-X Stars Business Accelerator, Inc. is a business incubator and accelerator with a charter goal to advance forward 15 cardiovascular related innovations and 15 social good impact innovations every 5 years. 3/4’s of all funding and man time invested is intended to go towards advancing the cardiovascular innovations portfolio and 1/4 toward the social good impact innovations. Most of the innovations brought into the incubator/accelerator emanate from the Leonhardt Ventures associated research laboratories and venture creation lab. At the time of entering the incubator the innovations are early stage developments that have not yet fully formed into companies. We call these “startups”. These innovations or “startups” are not registered as a stand alone C corporation until they are strong enough to stand on their own with limited financial and man power support from the incubator/accelerator and they can support and manage their own financial bookkeeping and separate tax returns. Until then they are Technology Platforms and “Startups” in the process of organizing into companies with experienced mentorship assistance.

• The securities may be sold only to accredited investors, which for natural
persons, are investors who meet certain minimum annual income or net worth
thresholds; > $200K individual income or $300K joint. > $1 million in assets excluding primary residence.
• The securities are being offered in reliance on an exemption from the
registration requirements of the Securities Act and are not required to comply
with specific disclosure requirements that apply to registration under the
Securities Act;
• The Commission has not passed upon the merits of or given its approval to the
securities, the terms of the offering, or the accuracy or completeness of any
offering materials;
• The securities are subject to legal restrictions on transfer and resale and
investors should not assume they will be able to resell their securities; and
• Investing in securities involves substantial high risk, and investors should be able to bear the
loss of their investment

RISK WARNING: The Cal-X Stars Business Accelerator, Inc. portfolio of innovations and startup companies are all early stage. The investment risk is very high and investors should be in position to lose all their investment without hurting their financial security. This 506c offering is limited to accredited investors only with > $1 million in assets excluding their primary residence. The offering will be posted on authorized accredited investor only portal sites that verify accreditation qualification such as www.crowdfunder.com, www.healthiosxchange.com, www.equitynet.com and www.angelist.co These portals and other outside service providers assist in verifying with reasonable assurance the accredited status of any potential investor. Merriman Capital http://www.merrimanco.com/ has been hired as an advisory registered broker dealer for this offering. Any potential investor should review all risks published within our private placement memorandum that is available upon written request to email hleonhardt@aol.com or via the above mentioned password protected portals.
Note – New 506c regulations allow general advertising and up to 2000 shareholders while remaining private –http://www.sec.gov/rules/final/2013/33-9415.pdf

Proposed Use of Proceeds $15 million 506D Part C Shares Offering 2018

Private Placement Memorandum

for Leonhardt’s Launchpads by Cal-X Stars Business Accelerator, Inc.

By product groups…

Heart & Cardiovascular (9) = $6,000,000 which includes $3 million to Second Heart Assist, Inc.

Brain (1) = $1,000,000

Cosmetic & Personal Care (6) = $3,500,000

Major Organ Regeneration (11) = $3,000,000

Cancer (1) = $1,000,000

Regenerative Economy (3) = $250,000

Offering Cost Expenses = $250,000

Current valuations and share prices are here > https://leonhardtventures.com/our-companies/#toggle-id-2

Link to our 2016/17 Annual Report – http://2ho06i23weps2hx3g346udzo-wpengine.netdna-ssl.com/wp-content/uploads/2017/11/cal-x_stars_annual-report_2017_v15_web.pdf

Business model = accelerate 6 startups each year through first-in-man results and opportunity to seek strategic partner/buyer each year for the next 5 years. Goal is 23X ROI on accelerator shares and 63X on individual startup shares after 5 years.

Investment into the accelerator is 2:1 meaning if an investor invests $30,000 they get $30,000 worth of accelerator shares and also at no additional charge warrant to acquire by Dec. 31 of the year they invested also $30,000 worth of individual startup shares within the accelerator of their choice. They can choose to allocate $1000 each in 30 startups by example, $10,000 each in three startups or all $30,000 of their warrant into their single favorite startup.

Note – By charter we are limited to 30 startups in our accelerator in any given annual portfolio class. In short durations where we may have more than 30 startups we are working towards a merger, sale or a cut to reduce back down to 30. In the case of DentaCell Accelerator we have an accelerator within the accelerator which expands the total number of startups under this sub-accelerator. We are considering merging now VibroCell assets into either Second Heart Assist, Inc. or BioLeonhardt as an example.

2018 Goals

Leonhardt‘s Launchpads by Cal-X Stars Business Accelerator, Inc.

2018 Portfolio of Startups/Licensable Technology Platforms (LTP’s)

Regenerative Medtech – Organ Regeneration

HEART AND CARDIOVASCULAR (9)

· BioLeonhardt – heart regeneration = complete animal studies and launch OUS clinical study > find strategic partner – www.bioleonhardt.com

· AortaCell – aorta regeneration = complete animal studies – https://leonhardtventures.com/aortacell/

· BioPace – biological pacemaker regeneration = complete animal studies – https://leonhardtventures.com/bio-pace/

· Valvublator – heart valve regeneration = finish prototype development and lab studies and launch animal studies – www.valvublator.com

· VibroCell (includes CoroStim) – vibrational energy to prevent clots, plaque, calcification = finish prototype development and lab studies + complete animal studies – https://leonhardtventures.com/vibrocell/

· HeartScore – genomics and bioelectric based heart failure, inflammation and stroke management = find strategic partner – www.heartscore.co

· VascuStim (formerly MyoStim Peripheral, includes EndoCell) – limb salvage regeneration, blood flow improvement for critical limb ischemia, diabetic leg and foot ulcer treatment, artery regeneration = complete international registry clinical study with multiple arms > find strategic partner – www.vascustim.com ;

· Second Heart Assist, Inc. – wireless powered chronic or temporary circulatory assist pump in aortic stent = complete animal studies and first-in-man studies for catheter 1st gen. device > find strategic partner. Complete lab and animal studies 2nd gen. wireless power – www.secondhearttinc.com ;

· PressureStim – bioelectric treatment of high blood pressure via improved arterial elasticity and bioelectric membrane potentials management = complete animal studies – https://leonhardtventures.com/pressurestim/

BRAIN (1)

· CerebraCell (includes CerebraCell Brain-N-Hance and CerebraCell Concussion) – brain regeneration, cognitive function improvement, concussion recovery = complete lab and animal studies – www.cerebracell.com ;

COSMETIC and PERSONAL CARE (6)

· Stem Cell Bra – breast regeneration = finish 2nd round of large animal studies. Launch first-in-man studies > find strategic partner – www.stemcellbra.com ;

· DentaCell Accelerator – dental gum regeneration + tooth pulp storage = launch tooth pulp storage business, develop new dental innovations & startup – www.dentacellaccelerator.com ;

· OrthodontiCell – bioelectric stimulator for accelerated tooth movement and freezing teeth positions straight = complete animal studies, complete first-in-man studies > find strategic partner – www.orthodonticell.com

· SkinStim – skin regeneration = launch OUS first-in-man studies – www.skin-stim.com ;

· MyoStim ED – bioelectric erectile dysfunction treatment = complete animal studies + launch OUS first-in-man studies – https://leonhardtventures.com/myostim-ed/

· HairCell – hair regeneration = launch OUS first-in-man studies > find a strategic partner – www.haircellstim.com

MAJOR ORGAN REGENERATION (11)

· EyeCell – eye regeneration = complete small and large animal studies – https://leonhardtventures.com/eyecell/

· PancreaCell – pancreas regeneration = complete animal studies – https://leonhardtventures.com/pancreacell/

· RegenaLung (includes ECMO-Cath) – lung regeneration (includes 50% owned subsidiary RegenaLung COPD) cannula for infusing oxygen directly into the blood using an oxygenator, a medical device that acts as an artificial lung = find research partner + complete animal studies – https://leonhardtventures.com/regenalung/

· LiverCell – liver regeneration = find a research partner (DUKE?) + complete animal studies – https://leonhardtventures.com/livercell/

· KidneyCell – kidney regeneration = find a research partner + complete animal studies – www.kidney-cell.com ;

· EarCell – ear hearing regeneration = find a research partner + complete animal studies – www.ear-cell.com ;

· BladderCell – bladder regeneration = find a research partner + complete animal studies – https://leonhardtventures.com/bladdercell/

· Polypstim-MucosaCell – sub-mucosa regeneration + bioelectric polyp, cyst and fibroid treatment = complete animal studies – www.polypstim.com

· InStim – bioelectric real time inflammation management = develop prototype + complete animal studies– https://leonhardtventures.com/leonhardt-team-launches-instim-bioelectric-customized-inflammation-control/

· OrthoStim– bioelectric joint recovery treatment = conduct clinical registry study USA – www.ortho-stim.com ;

· BioLeonhardt Whole Body Regeneration – whole body regeneration and Bod-Stim bioelectric yoga and athletic pants = secure SBIR grant add CIP claims to patent + build and test body suit prototypes – https://leonhardtventures.com/bioleonhardt-whole-body/

CANCER TREATMENT (1)

· CancerCell – bioelectric cancer tumor treatment + regeneration = complete lab + animal studies and launch first-in-man studies OUS > find strategic partner – www.cancercellinc.com ;

REGENERATIVE ECONOMY (3) – Designed primarily to raise non-dilutive to shareholders founds for organ regeneration research.

* The California Stock ExchangeTM – capital raising platform in partnership with others for biotech, medtech and social good impact companies. 50% proceeds to organ regeneration research = promote social good impact Motif fund and partner with a major exchange www.calstockexchange.com

* Kindheart Lionheart Media & Publishing – social good impact and medtech media company. 50% proceeds to organ regeneration research. www.kindheartlionhearttv.com
* Lionheart Brands Food & Beverage – Food and beverage products with 50% of proceeds going towards organ regeneration research. https://app.slidebean.com/p/MaZtimNH9h/Lionheart-Cooperative-Marketing-

Brief quick elevator pitches for startups in 2017 … – Leonhardt Ventures

Our Financials in Comparison to Nearest Competitors

At our board and shareholder meeting today we reported a first draft – un-reviewed and un-audited – reported 2015 loss of (-$275,000).

Quick look at the financials of our nearest competitors for comparison purposes:

Cytori Therapeutics of San Diego – http://www.cytori.com/ ;the recognized leader in adipose cell derived regenerative therapies

Financials – http://finance.yahoo.com/quote/CYTX/financials

2015 – Lost (-$19,405,000)

2014 – Lost (-$38,437,000)

2013 – Lost (-$26,177,000)

Capricor of Los Angeles – http://capricor.com/ – the recognized leader in cardiac stem cell derived regenerative therapies.

Financials – https://finance.yahoo.com/quote/capr/financials?ltr=1

2015 – Lost (-$12,857,339)

2014 – Lost (-$6,216,592)

2013 – Lost (-$8,891,924)

Cal-X Stars Business Accelerator, Inc. Executive Summary – Short Version

Cal-X Stars Business Accelerator, Inc. was founded in Santa Monica, California in 2013 by Howard J. Leonhardt as a spin out of Leonhardt Ventures with the purpose to accelerate forward cardiovascular and social good innovations from early development stage to exit within 3 to 5 years. Howard J. Leonhardt is an inventor with over 20 issued patents in the cardiovascular field http://patents.justia.com/inventor/howard-j-leonhardt and a serial entrepreneur. Over 200,000 patients have been treated with Leonhardt inventions to date generating over $3 billion in revenues. He is most noted for inventing and bringing to market the TALENT (Taheri-Leonhardt) stent graft for aortic aneurysm repair without surgery.

The TALENT (Taheri-Leonhardt) stent graft for thoracic aortic aneurysm repair reduced mortality from 5.7 to 11.7% down to 1.9 to 2.1% and serious adverse events such as stroke rates from 33% down to 9% –http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3036454/ in patients with a thoracic aortic aneurysm. In hospital mortality for complicated Type B Thoracic Aortic Dissections were reduced from 33.9% down to 10.6% –http://interventions.onlinejacc.org/article.aspx?articleid=1110156 + http://www.medtronic.com/for-healthcare-professionals/products-therapies/cardiovascular/aortic-stent-grafts/talent-thoracic-on-captivia/

Short History of Howard Leonhardt and Leonhardt Ventures

1980’s – Developed world leadership in turn-key cath labs and critical care units. Patented, manufactured and achieved world leadership in polyurethane balloon cardiovascular balloon catheters. Produced custom balloon catheters for NASA. Reached $3.2 million in sales in 1987 and profitability. Developed in partnership with Labcor an implantable heart valve. Developed in partnership with DMG a blood oxygenator. Developed first electrical stimulation devices for improving blood flow.

1990’s – Developed first intravascular lung catheter PENSIL. Developed and patented first vibrational energy gas exchange improvement devices. Built custom balloon catheters for Cordis Corporation. Built radiation delivery catheters for Novoste for preventing restenosis after stent placement. Developed first percutaneous heart valve. Developed first commercially successful stent graft for aortic aneurysm repair TALENT (Taheri-Leonhardt). Patented first stem cell delivery catheter (PRO-CELL). Grew from 35 employees to over 500. Merged with Arterial Vascular Engineering, Inc. April of 1998. Sold to Medtronic, Inc. January of 1999.

2000- 2008 – Founded first stem cell company for heart repair. Completed first-in-man case of stem cell repair of a heart without surgery in early 2001. Developed MyoCath stem cell delivery system. Introduced first cardiovascular genetic test on U.S. market in 2000 – the PLa2 test. Developed line of @ home heart failure monitors. Raised over $105 million in capital for stem cell research for heart failure. Advanced to Phase III clinical trials stem cell therapy for heart repair – MyoCell treated pts improved 95.7 meters in exercise capacity over placebo pts that came in at minus 4 meters decline. Completed the only biotech IPO on the whole USA in 2008 at $76 million valuation on NASDAQ @ $5.25 a share.

2008 to present – Founded Leonhardt’s Launchpads laboratory in California for research on cardiovascular and social good impact innovations. Helped in getting the JOBS ACT passed to reduce the cost of complexity of small firms raising capital. Numerous patents on electrical stimulation devices that control the homing of stem cells to specific sites in the body and then the differentiation of those stem cells to useful tissues. Developed first implantable stem cell pump. Developed heart valve decalcification and cell sodding device. Invented world’s first Stem Cell Bra (patent pending) that recruits with homing signal a woman’s own stem cells to her breast tissue to augment size and shape. Developed working collaborations with Cardiobridge, Procyrion, Core Manufacturing and other strategic partners.

Cal-X Stars Business Accelerator, Inc. is a venture creation lab, incubator and business accelerator which is majority owned by Leonhardt Ventures (Leonhardt Vineyards LLC DBA Leonhardt Ventures). At the completion of this current $15 million offering Leonhardt Ventures will own 50.1% of Cal-X Stars Business Accelerator, Inc. and outside investors, mentors, management staff and advisory board members will own 49.9%

All the but 3 of the 15 class of 2014 cardiovascular innovations portfolio are Leonhardt Ventures founded inventions, products and projects launched by Howard J. Leonhardt. Cardiobridge and Procyrion the two implantable temporary circulatory assist pump systems were developed independently. Leonhardt had been working on these two same developments in his own lab and ran into the Cardiobridge and Procyrion teams working on very similar designs and decided to join forces instead of competing. Core Manufacturing www.core-manufacturing.com was a spin out of the Alfred Mann Foundation and was formed and funded independently. Core Manufacturing is the Leonhardt Ventures cGMP manufacturing partner for pumps, pacers, stimulators and sensors. Leonhardt Ventures has provided the lions share of all funding to patent and prove out these inventions and innovations to date. Leonhardt Ventures and Leonhardt’s Launchpads screens thousands of opportunities and only chooses the few best of the best, and the most well proven out, to enter into the Cal-X Stars Business Accelerator. By charter the Cal-X Stars Business Accelerator will never exceed the limit of accelerating more than 15 cardiovascular innovations at one time. The only way a new innovation or startup may enter the accelerator is if one of the current product development projects is sold, licensed or dropped.

Howard Leonhardt founded Bioheart, Inc. in early 1999 and remained as CEO up to March of 2007 just before its $76 million valuation IPO on NASDAQ in 2008. In 2008 Leonhardt moved from Florida where Bioheart was headquartered and came out California to establish his research laboratory and incubator/accelerator. He was assigned by Bioheart that year to find homes for his own patents, and a few others he acquired with funding he provided himself directly, that they were not developing on their own due to their intense focus on MyoCell and AdipoCell only. Bioheart will receive a 3% royalty on sales or 10% of capital raised for products commercialized that directly read on the claims of those particular patents. It was quickly realized that more data was needed to support the value of those patented inventions before lucrative license deals could be struck and Leonhardt began the work of gathering that data and securing additional new patents. He also got to work in establishing the research collaborations necessary to get this work done and published in peer reviewed journals and presented at major meetings. He established a 35 person Scientific Advisory Board comprised of the leading stem cell scientists, cardiologists, heart failure specialists, vascular surgeons and electro-physiologistshttps://calxstars.com/scientific-advisory-board/ and a 70 person business management team, mentorship brain trust and advisory board – http://www.calstockexchange.com/team-cal-x/ He financed all these developments from 2008 to 2014 100% on his own up to this current financing where he has opened up for the first time for outside investors to participate in the commercial opportunities for these inventions and innovations via a Reg D 506c offering of Cal-X Stars Business Accelerator, Inc. stock.

8 of the 15 innovations or startups in the social good impact portfolio were founded, developed and totally funded to date by Leonhardt Ventures. Degreed, Chic-CEO, EquityNet, Crowdfunder, Healthiosxchange, Stiletto Dash and The Task Runners were all formed independently outside of Leonhardt Ventures Note- Artists Cafe NYC, KoffeeHouse Music, Radio Veronica USA, Right Clearing, Crowdfund, Lions Den, California Love) all fall under one entity Kindheart Lionheart Media Co. on our charts meaning the accelerator invests in Kindheart Lionheart Media Co. and they invest on in their own portfolio of alliance partners and innovations. 2nd Note – Leonhardt Ventures and Cal-X Stars Business Accelerator, Inc. utilizes The Task Runners for office support services such as payroll, bookkeeping, tax return preparation, scheduling and more.

We specialize in two clear focus areas:

1. Cardiovascular therapies.
2. Social good impact innovations that can benefit from crowdfunding.

The Cal-X Stars Business Accelerator, Inc. generally earns 6 to 9% seed stage equity in the innovations and startups in the accelerator in exchange for mentorship assistance and access to its network of industry contacts and scientific advisory board. Additional sweat equity is earned by underwriting the cost for the portfolio class startups to participate in up to 20 cardiology or social good impact/crowdfund financing meetings a year often with an exhibit booth, press releases, promo flyers and a side showcase in a nearby conference room.

The principle of the balance of the fund is this…

1. Cardiovascular innovations will take a minimum of 3 years to be in position to be sold at a good price.
2. The cash flow positive social good impact innovations can provide cash flow positive balance to the accelerator via the 3% of top line sales royalty agreement while we wait for the cardiovascular innovations to be sold in year 3 to 5 of development.
3. The social good impact innovations require substantially less up front capital before becoming profitable.
4. Being in the social good impact financing world we meet potential great backers of our cardiovascular innovations which by nature are social good as well.

In addition to sweat equity Cal-X Stars Business Accelerator, Inc. may acquire additional equity positions in the startups at any stage of development via direct investment. The target goal is to reach about a 20% seed stage equity position before outside VC financing is secured.

> Cal-X Stars Business Accelerator, Inc. strives to receive a 3% of top line sales royalty for the first full three years of full scale commercialization of each product developed in its accelerator as one form of return on investment.
> By charter all cardiovascular portfolio startups in the accelerator agree to the plan to auction their company off to the highest bidder in year 3 to 5 of development with whatever data and patents are available at the time.
> By charter all Cal-X Stars Business Accelerator, Inc. shareholders receive their pro-rata share of the sale or license of any asset on the exact moment of closing of the sale of that particular asset (in this way winning innovation returns are not washed out by losers in the portfolio).
> By charter all social good impact innovations must be cash flow positive within 12 months of entering the accelerator.

Leonhardt Ventures’ Cal-X Stars Business Accelerator Raising $15 million

Accelerator and innovation laboratory focused on cardiovascular technologies and social good impact enterprises

SANTA MONICA, Calif., Nov. 18, 2013 /PRNewswire/ — Cal-X Stars Business Accelerator, Inc. is an innovation accelerator with an unprecedented portfolio of breakthrough cardiovascular life science and high social good impact innovations that have primarily been majority funded to date by Leonhardt Ventures and its associated angel investor network.

The innovation laboratory and business accelerator has two clear focus areas:

Cardiovascular innovations with a focus on heart failure and stem cell therapies.
Social good impact innovations designed to be cash flow positive short term.

Management team and board have a proven track record in leading breakthrough innovations in these focused spaces – http://www.calstockexchange.com/team-cal-x/

Cardiovascular portfolio technologies include…

MyoStim Pacers – http:/www.myostimpacers.com – heart failure pacemaker designed to recruit reparative stem cells to damaged and weakened heart tissue.

Bioheart, Inc. – http://www.bioheartinc.com – Phase III leader in applying adult muscle stem cells to treat advanced heart failure since 1999. Only cell type known to grow new contractile muscle in the depths of heart scar tissue.

BioPace – biological pacemaker made entirely of living cells.

CoroStim – world’s first vibrational energy emitting pacemaker designed to prevent plaque formation in high risk coronary arteries.

AortaCell unit of Stemergy – wireless non-invasive energy device designed to recruit stem cells to weakened vessel wall tissue for repair. Stemergy is developing a full line up of wireless energy devices designed to direct stem cell therapies non-invasively.

BioLeonhardt – http://www.bioleonhardt.com – combination electrical stimulation and multi-stage cell and gene therapy method, composition and devices for treating advanced heart failure. Featuring combined utilization of MicroRNAs, nutrient time release SDF-1, hydrogel, cardiac stem cells, iPS cells and muscle progenitor stem cells. First method to utilize an implantable stem cell pump for multiple dosages of delivery of stem cells and growth factors over time.

Cardiobridge – http://www.cardiobridge.com – high flow rate 10FR circulatory support catheter pump in clinical testing for acute decompensating heart failure and high-risk PCI.

Procyrion Implantable Heart Pumps – www.procyrion.com – the Procyrion device consists of a small, continuous flow pump mounted within a self-expanding anchoring system. The device is advanced through a catheter in the femoral artery to the descending thoracic aorta. The self-expanding anchors deploy to fix the pump to the aortic wall.

HeartScore – www.heartscore.co – composite scoring system of genetic, blood and artery scan test results that are loaded into the SecondBeat wearable wrist watch.

Stem Cell Pump – implantable stem cell pump designed for controlled dose delivery of stem cells and selected growth factors over time to specific target organ locations.

LVSens – implantable heart sensor.

Stem Cell Bra – www.stemcellbra.com – the world’s first women’s bra designed to recruit her own stem cells with a homing signal and to build new breast tissue without surgery – patent pending. Clinical safety and efficacy test results pending.

CORE Manufacturing LLC – http://prn.to/169qrpw – cGMP contract manufacturing service for bioactive implantable devices.’

The Leonhardt Ventures’ Cal-X Stars Business Accelerator, Inc. Scientific Advisory Board is made up of leading heart failure physicians, stem cell scientists, cardiologists and electrophysiologists – https://calxstars.com/scientific-advisory-board/.

Note – Bioheart will receive royalties and milestone payments from MyoStim Pacers, BioPace and BioLeonhardt.

Social Impact Crowdfunding Portfolio include…

The California Stock Exchange – designed to be the first conscious capitalism stock exchange that facilitates local investing –www.calstockexchange.com – the new home marketplace for people that believe doing good is not just good for good sake but is good business. Companies focused on long term growth with a sense of purpose. SEC registration is required.

Cal-X Crowdfund Connect – Crowdfunding resources center – www.calxcrowdfund.com

Link to recent Cal-X Press Release: http://www.prnewswire.com/news-releases/cal-x-crowdfund-connect-selects-earlyiq-for-diligence-and-transparency-services-to-protect-investors-215508961.html

Crowdfunder.com – equity crowdfunding leader Title II and coming soon Title III – CrowdImpact and CrowdFundX – www.crowdfunder.com ;

ZimpleMoney – Microloans platform www.zimplemoney.com ;

Food Trikes & Scooters – mini electric powered food trucks combined with complete entrepreneurial support network partnered with InVenture –www.foodtrikesandscooters.com ;

Kindheart Lionheart Media Co. – inspirational books, movies and music – www.kindheartlionheart.com ;

Radio Veronica USA, Starfunder.com, Koffeehouse Music, Local DJ Radio and RightClearing – crowdfunding music publishing rights with one tap of your smart phone surface while listening – www.radioveronicausa.com + www.rightclearing.com + www.koffeehouse.com

Degreed.com – digital degree granting college credit for online courses “jail breaking the college degree” revolutionizing lifelong education – www.degreed.com

EquityNet – business plan analysis and development software and crowdfunding tools – www.equitynet.com

Chic-CEO – women entrepreneurs network 50,000+ strong and growing – www.chic-ceo.com

“Other leading accelerators launch up to 16 new startups every 12 weeks in all sectors of business. Our approach is much more focused and longer term. We only accelerate cardiovascular and social good impact innovations. A maximum of 14 companies in each sector every 5 years. We take our cardio portfolio companies on the road to over 20 cardiology meetings a year and showcase our social good impact companies at conferences such as CrowdImpact, The Conscious Capitalism Summit, Tech.co and The California Women’s Conference.” stated Howard Leonhardt, Founder & CEO.

About Leonhardt Ventures: Since 1982 Leonhardt Ventures has a strong history of inventing, developing, backing and bringing to market leadership products for treating heart and cardiovascular disease. Over 200,000 patients have been treated to date with Leonhardt inventions. Leonhardt Venture’s started the Cal-X Stars Innovation and Business Accelerator in 2012 to guide forward cardiovascular and social good impact innovations over a 5 year period in preparation for a listing on the future California Stock Exchange (SEC registration application in process). June 11th, 2013 Leonhardt Ventures announced that it has chosen CORE Manufacturing LLC in Valencia, California for manufacturing and product development services for its lineup of active implantable devices – http://online.wsj.com/article/PR-CO-20130611-906181.html

About Cal-X Stars Business Accelerator, Inc: Founded in 2012 as a spin out of Leonhardt Ventures innovation laboratory and Leonhardt’s Launchpads as a 5 year business and innovation accelerator focused on cardiovascular technologies and social good impact innovations.

Contact: Howard Leonhardt, Leonhardt Ventures’ Cal-X Stars Business Accelerator, Inc., 1531 6^th Street, Unit 401, Santa Monica, California, 90401, Office direct 310 310 2534, Email

RISK WARNING: The Cal-X Stars Business Accelerator, Inc. portfolio of innovations and startup companies are all early stage. The investment risk is very high and investors should be in position to lose all their investment without hurting their financial security. This 506c offering is limited to accredited investors only with > $1 million in assets excluding their home and vehicles. The offering will be posted on authorized accredited investor only portal sites that verify accreditation qualification such aswww.crowdfunder.com, www.healthiosxchange.com, www.equitynet.com and www.angelist.co Merriman Capitalhttp://www.merrimanco.com/ has been hired as an advisory registered broker dealer for this offering. Any potential investor should review all risks published within our registered private placement memorandum that is available upon written request or via the above mentioned password protected portals.

Note – New 506c regulations allow general advertising and up to 2000 shareholders while remaining private – http://www.sec.gov/rules/final/2013/33-9415.pdf

This press release distribution was issued via Local PR Media, a division of PR Syndication.

Read more news from Leonhardt Ventures.

SOURCE Leonhardt Ventures

RELATED LINKS
http://www.leonhardtventures.com

CROWDFUNDING V. RULE 506(C) OFFERINGS

506C TITLE II OFFERINGS ARE LIMITED TO ACCREDITED INVESTORS –

S.E.C. DEFINITION VIA THIS LINK – HTTP://WWW.SEC.GOV/ANSWERS/ACCRED.HTM

VERIFYING ACCREDITED STATUS OF INVESTORS IS REQUIRED

Four Methods

For individual investors, you will be deemed to have taken reasonable steps if you use one of the following four methods.
1) For investors accredited on the basis of income, you review their tax returns, a Form W-2, a Form K-1, or a Form 1099 for the two (2) most recent years and obtain from them a written representation that they have a reasonable expectation of reaching the income level necessary to qualify as an accredited investor during the current year.
2) For investors accredited on the basis of net worth, you review one or more of the following types of documentation dated within the prior three (3) months and obtain a written representation that all liabilities necessary to make a determination of net worth have been disclosed:
(i) With respect to assets: bank statements, brokerage statements and other statements of securities holdings, certificates of deposit, tax assessments, and appraisal reports issued by independent third parties; and
(ii) With respect to liabilities: a consumer report from at least one of the nationwide consumer reporting agencies.
3) You obtain a written confirmation from one of the following persons that they have taken reasonable steps to verify that the purchaser is an accredited investor within the prior three (3) months and have determined that such purchaser is an accredited investor:
(i) A registered broker-dealer;
(ii) An investment adviser registered with the Securities and Exchange Commission;
(iii) A licensed attorney who is in good standing under the laws of the jurisdictions in which he or she is admitted to practice law; or
(iv) A certified public accountant who is duly registered and in good standing under the laws of the place of his or her residence or principal office
4) For accredited investors who purchased your securities before September 23, 2013, and who continue to hold such securities, for any new purchases in your 506(c) offering, you obtain a certification by such person at the time of sale that he or she qualifies as an accredited investor.

506c Title II Offering for Accredited Investors (verified and password protected) Only @
healthiosxchange.com/capitalsource/LeonhardtVenturesCal-XStars‎
Jan 14, 2014 – Cal-X Stars Business Accelerator, Inc. is meant to be a feeder of star cardiovascular and social good impact companies to Cal-X The California .. HealthiosXchange – Leonhardt Ventures’ Cal-X Stars

1Q 2014 Newsletter and 2013 Annual Report « Cal-X Stars
calxstarsstg.wpenginepowered.com/1q-2014-newsletter-and-2013-annual-report/‎
Leonhardt awarded by U.S. PTO Trademark for The California Stock Exchange … Cal-X Stars Business Accelerator, Inc. Launches $15 million Raise under 506c …

Disclaimer: Our newsletter and annual report are assembled by a small staff and we by charter move quick under the motto “Ready, Fire, Aim”. Our newsletters and annual report are subject to errors and omissions and will regularly be updated, modified and corrected where mistakes have been made. The same remains true of our web sites. Our newsletters, web sites and annual report are meant to be a general reflection of the direction of our activities but are not meant to be an exact precise comprehensive description of all related risk factors. In many instances required important patent protection or important agreements of collaboration are not yet fully secured in writing and finalized, although it may be the intent of the organization to pursue those directions. If you have any questions for clarification about any particular item of importance to you, please email Howard Leonhardt directly at hleonhardt@aol.com. The short bullet point nature of the newsletters and annual report highlight positive progress points on our project developments but do not comprehensively list obstacles, risk factors, setbacks, delays or other related problems. Do not rely on these materials for any investment decision. Our organization holds as a strategy moving very quickly on bringing multiple innovations forward with a very small staff with very low starting budgets under the motto “try a lot of stuff and keep what works”. This type of strategic plan for building a company and driving forward innovation is not a fit for all types of investors. We believe in learning by doing and by charter have built in by design the need to make mistakes in the innovation process under Tom Peter’s two mottos for innovation “fail forward fast and reward excellent failures and punish mediocre successes”. Our organization by design strives to make disruptive first in the world breakthroughs in innovation, which by nature is difficult and wrought with risk of failure. This is not for everyone and certainly not sound for a conservative investment strategy. Refer to the company Private Placement Memorandum including all risk factors published for a better understanding of related risks Click Here

SEC FORM D – Securities and Exchange Commission

Notes regarding financial forecasts in Private Placement Memorandum of Cal-X Stars Business Accelerator, Inc.:

The 5 year financial forecasts in the Cal-X Stars Business Accelerator, Inc. were prepared by George Georgallidis an MBA graduate from Pepperdine University and Sukaina Alarakhia, PhD – Financial Analyst based on input and assumptions provided by Howard J. Leonhardt, Founder, Executive Chairman and CEO.

Assumptions and inputs to financial forecasts:

1. The cardiovascular innovations portfolio has by plan intention to exit within 3 to 5 years by a Dutch auction with the data available at the time.
2. Cameron Health, World Medical Manufacturing Corp., Arterial Vascular Engineering and NanoStim were used as primary reference comparables for the cardiovascular portfolio.
3. The portfolio of innovations and startups address very large markets = 1. Heart failure. 2. Arterial disease. 3. Lower limb ischemia. 4. Breast augmentation without surgery. 5. Diabetic foot uclers. 6. Heart valve calcification. 7. Aortic aneurysm disease. 8. Social good impact investing. 9. Online education. 10. Inspirational media.
4. The founding teams and advisory boards have track records in taking products from concept to market leadership.
5. By charter we only accept social good impact innovations in our portfolio that expect to be cash flow positive within 12 months of funding and entering the accelerator mentoring program.
6. The founding teams and advisory board have track records in building strong intellectual property estates.
7. The company strategy of developing never before tried breakthrough first ever innovations is the equivalent in baseball of swinging for the fences for home runs which correlates with increased risk of strike outs (total loss). This has been communicated throughout all our materials repeatedly. We also have published our commitment to Tom Peters taught innovation strategies of try a lot of stuff and keep what works, fail forward fast + ready, fire, aim and rapid prototyping and trial balloons for rapid feedback loops.
8. We in no way make any sort of promise for high returns. In fact just the opposite we make clear that our strategy is a high risk strategy NOT appropriate for any nest egg type investments. We communicate only that we are trying to cure heart failure and undertake other great leaps forward in innovation, with bold new never tried before inventions. We communicate clearly that many others have tried before to conquer heart failure and have failed to prove better safety and efficacy than existing therapies. Conquering heart failure is not expected to be easy in any way and we make this clear. Our other goals as an organization are nearly on the same scale of loftiness and difficulty ie; creating the first conscious capitalism stock exchange in the USA, developing the first biological pacemaker made of living cells, developing the first wireless energy systems to non-invasively direct stem cell repair of organs and tissues without surgery, vibration energy systems to prevent arterial plaque formation in arteries, the first stem cell recruiting and muscle growing heart pacemaker, the first ever implantable stem cell pump and electrical stimulator combination device.
9. Our clear stated goal with the cardiovascular innovations is to sell them off in 3 to 5 years in auction with whatever data is then available (hopefully minimum of 30 OUS patients) to one of the leaders in the space which include; Medtronic Inc, Boston Scientific Guidant, St. Jude Medical, Abbott Labs, Johnson & Johnson, Novartis, Amgen, Genentech, Sorin Biomedica, BioTronik, Terumo, AbioMed, HeartWare, Thoratec or Edwards.
10. We communicate clearly that it is nearly impossible to predict the five year out financial forecasts of very early stage developments that are attempting to be brand new breakthrough disruptive innovations, that have never been tried before, where no true benchmark comparison exists.

Cal-X Stars Business Accelerator, Inc. Financial Analyst Advisor Sukaina Alarakhia, PhD – Financial Analyst – Qualifications and Experience

Research Areas:
1. Corporate Governance: Board Structures, Board Composition, Board Performance.
2. Mergers and Acquisitions: acquisition strategy, acquisition motives, transaction types, acquisition failures/successes, determinants of premiums.
3. PE & VC Industry
4. Innovation in Health Care & Life Science.
Dissertation: “An Examination of the Relationships between Acquirer’s Board Vigilance Factors and Premiums Paid in Acquisitions”
Career Interests: Investment/competitive analysis and due diligence in life science, health care and high tech, M&A analyst, Management Consulting, Proxy Research and Proxy Solicitation, Private Equity, Venture Capital, Economic Development and Research Policy.
Industry interests: Life Science, Mobile Healthcare, Wireless Life Science, Clean Tech, Hi Tech.
Experience
Analyst
Moore Venture Partners
January 2014 – Present (1 month)San Diego
05/12 – 12/13 Intern; 01/14 – Present: Analyst
Intern
Index Fund Advisors, Inc.
November 2013 – Present (3 months)Irvine, CA
Analyst
Tech Coast Angels
March 2012 – January 2014 (1 year 11 months)
03/12 – 12/12 Analyst Intern; 01/13 – 07/13 Deal Analyst
Key member of a team evaluating early stage life science and technology companies for investment opportunities
•    Sourced deals, conducted initial screenings and preliminary due diligence on early to growth-stage companies
•    Understood business models, competency of executive teams, ownership and finance structures
•    Performed competitive analysis to understand strengths, weakness, opportunities, and threats
•    Conducted additional financial, market, intellectual property, and company due diligence
•    Compiled, analyzed, and reported quarterly data on deal flow and company screenings
•    Brought in additional $314 K in outside funding for series B round for an emerging specialty pharma company
About Tech Coast Angels (TCA)
TCA is the largest angel investment organization (in terms of portfolio size) in the United States, with over 300 members in five regional networks covering all of Southern California. Members have invested over $120 million in approximately 200 companies since TCA’s inception in 1997. TCA’s portfolio companies have attracted over $1 billion in additional investment, and several of them have recently achieved successful liquidity events though acquisition or the IPO market.
Board Member – Operations Chair
Association for Strategic Planning
August 2005 – January 2014 (8 years 6 months)San Diego, CA
(Open)1 recommendation
Timi Gleason
Leadership & Group Coach; Virtual Strategic Planner; Stakeholder-Centered; Org Dev-HR Mentor
The San Diego Association for Strategic Planning (ASP) is small and mighty and without Sukaina as our Operations Chair, we wouldn’t be so mighty. As a volunteer, she is dependable, organized, creative and extremely hard-working. She communicates…View
Senior Consultant and Postdoctoral Research Associate
General Informatics LLC
September 2010 – December 2013 (3 years 4 months)
Project A: Technology commercialization and innovation cluster-building project for the U.S Environmental Protection Agency (EPA) in its efforts to have Cincinnati become a known center for research and commercialization of innovative water technologies.
Project B: Innovation Fund project for Serbia, funded by European Union and World Bank
•    Reviewed and evaluated early-stage innovative start-ups across wide industries in Serbia that applied for funding to assess their eligibility and qualifications based on the Innovation Fund’s funding criteria.
About General Informatics
General Informatics LLC is an international economic development, research and policy consultancy, providing industrial, science, and technology advise toward policy making in attracting, launching, and retaining innovative technology companies for regional wealth. Clients include governments, agencies, authorities, and research institutes.
(Open)1 recommendation
Fred Phillips
Professor at SUNY Stony Brook: Technology-based economic development; Higher Education; Research & Policy
Sukaina is prompt, thorough, bright, and personable, and has produced excellent work in our project with General Informatics LLC for the Environmental Protection Agency. She and I have also worked together at CONNECT in San Diego, advising start-up…View
Corporate Development Intern
Apricus Biosciences
February 2012 – June 2012 (5 months)
Conducted foundational research and analysis to support the executive team’s business decisions involving strategic alliances
•    Researched, gathered and organized information on a newly in-licensed product for the purpose of partnering the product with additional pharmaceutical companies
•    Identified strategic partners within Apricus’ therapeutic areas for potential licensing and strategic partnerships
Springboard Fellow, Research Analyst and Finance Domain Expert
CONNECT
November 2011 – April 2012 (6 months)San Diego, CA
As Analyst: Identified start-up successes; analyzed and reported quarterly and annual trends on economic impact, venture capital funding, mergers and acquisitions, private placement, initial and follow-on public offerings activity.
As Domain Expert: Assisted startups in high-tech, biotech, medical devices, wireless and media industries, seeking early stage advice and funding. Advised on financials, market analysis, competitive positioning, and strategic direction.
About CONNECT – Catalyzing the creation of innovative technology and life sciences companies in San Diego
CONNECT, originally founded by University of California San Diego (UCSD) in the mid 80s and spun out of the university in 2005, has assisted in the formation and development of more than 3,000 companies in the San Diego region and is widely regarded as one of the world’s most successful organizations linking inventors and entrepreneurs with the resources they need for commercialization of innovative products in high tech and life sciences. The program has been modeled in more than 50 regions around the world. CONNECT has been recognized by Time, Inc. and Entrepreneur magazines and in 2011 won the national State Science and Technology Institute’s 2011 Excellence in Tech Based Economic Development Award for Building Entrepreneurial Capacity. In 2010 CONNECT was the recipient of the Innovation in Economic Development Award from the U.S. Department of Commerce for creation of Regional Innovation Clusters. CONNECT manages the San Diego, Imperial Valley, Inland SoCal Innovation Hub (iHub) designated by the state of California Governor’s Office of Business & Economic Development in 2010. Key to success has been the unique “culture of collaboration” between research organizations, capital sources, professional service providers and the established industries.
Founder
TheDealToday.com
July 2009 – July 2010 (1 year 1 month)
Online retail store displaying one product a day. Voted top ten by KillerStartups within first 3 months of launch date.
Assisted 5 start up ventures
While at School
February 2007 – September 2009 (2 years 8 months)
•    Analyzed initial business model, identified additional revenue sources, researched targeted population and competition, provided strategic and financial recommendations
•    For an online retail store: Developed market strategy to generate leads and sales from website traffic: affiliate marketing program, PR via online press release, blogs, email marketing campaigns
•    Helped connect ventures to start-up and early-stage investors
•    Provided support and recommendations on day to day operations, pricing strategies, marketing, branding, financials, and immediate and long-term strategies
Strategic Management Project
Meals-On-Wheels (MOW) Greater San Diego
June 2006 – August 2006 (3 months)
Observed and evaluated board’s and key executives’ strategic management process for CEO; offered three recommendations.
Summer Project – Acquisition Analyst
WD-40 Company
June 2005 – July 2005 (2 months)San Diego, CA
Identified 308 products as potential acquisition targets for CEO; narrowed to two targets most suited to WD40′s strategic objectives.
International Trade Intern
World Trade Center San Diego
January 2005 – May 2005 (5 months)
Participated in WTC’s new initiative to identify specific biotech and telecom companies in India seeking to form strategic partnerships with U.S clients.
Project Manager for a Strategy Class Consulting Project
SONY Corporation – Robotics Division, AIBO
January 2005 – March 2005 (3 months)
Performed strategic market segmentation and strategic diagnosis on SONY’s North American AIBO (Robot) division to measure its optimum strategic performance positioning.
Documentation Support Specialist, while attending MBA school
JPMorganChase
March 2001 – January 2004 (2 years 11 months)
Documentation Support Specialist 03/2001-01/2004
Responsible for all documentation serving the U.S Western Region, and assisted senior management with special strategic projects, audits, and six-sigma initiatives.
Marketing Intern
General Motors Marketing Internship
March 2000 – June 2000 (4 months)San Diego, CA
Worked with team members; conducted advertising, marketing, project management and budgeting functions
•    Analyzed qualitative and quantitative data from consumers to determine commercial viability of product
•    Assisted in planning of promotional event by generating sponsors, coordinated media strategy, press releases, created and executed ad campaigns; resulted in a 75% increase in product exposure
Teaching Assistant and Computer Lab Assistant
United States International University – Nairobi, Kenya
March 1997 – March 2000 (3 years 1 month)
•    Assisted Information Systems Professor with class teaching and prep work
•    Developed training manuals; Provided training and support to students and faculty in using various software applications
•    Successful at installing hardware/software, setting up user accounts and trouble shooting
Consultant to Senior Executive Team
Gulf Air
December 1997 – January 1998 (2 months)Dar es Salaam, Tanzania
Assigned to study percentage decline in annual sales in comparison to competitor airline Emirates.
ISP Team Member
Raha.com
December 1996 – January 1997 (2 months)Dar es salaam, Tanzania
Worked with founding team to launch Tanzania’s first ever internet service provider, HeartbeatOnline, now named Raha.com
Assistant Manager
Friendly Travel and Tours, part-time and concurrent with schooling
January 1990 – September 1996 (6 years 9 months)Mombasa, Kenya
Management, sales, marketing, ticketing, and advertising.
•    Increased overall sales with addition of new travel organization by 30%
•    Increased bookings by 90% over a 3-month period
•    Designed and marketed tour packages to both international and domestic clients
•    Recognized for offering top quality service, saving clients time and money
Publications
Life Science Cluster Report, Kansas region.
September 2010
Honors & Awards
Dorothy L. Harris women’s award in leadership
Alliant International University – Marshall Goldsmith School of Management
May 2010
Sumner Alpert Award lifelong learning in strategic management
Association of Strategic Planning
February 2007
Additional Honors & Awards
-Dorothy L. Harris women’s award for Leadership, 2010
-Sumner Alpert Award for lifelong learning in strategic management, 2007
Skills & Expertise
Most endorsed for…
55Start-ups
47Entrepreneurship
46Strategy
39Business Strategy
29Management Consulting
25Strategic Partnerships
23Mergers & Acquisitions
17Business Development
14Venture Capital
14Market Analysis
Sukaina also knows about…
13Research
13Competitive Analysis
11Corporate Development
11Due Diligence
9Analysis
8Management
7Lifesciences
7Strategic Planning
7Business Planning
6Financial Modeling
5Private Equity
5Program Management
5Financial Analysis
5Project Management
4Angel Investing
See 9+
Education
Alliant International University, formerly United States International University-San Diego Scripps Ranch
DBA, Business Administration, Concentration: Strategic Management
2005 – 2010
Doctoral Research: Mergers and Acquisitions and Corporate Governance
Activities and Societies: •    Sigma Iota Epsilon, member – USIU Chapter •    Deans List
(Open)1 honor or award
Alliant International University, formerly United States International University-San Diego Scripps Ranch
MBA, International Business, concentration: Management Information Systems
2000 – 2002
Activities and Societies: Student Government Association – Graduate representative of the College of Business; Sigma Iota Epsilon
United States International University – Nairobi, Kenya
BS, International Business Administration, Dual major: Management Information Systems (MIS) and Marketing
1996 – 2000
Transferred to San Diego Campus in 2000 Spring Quarter.
(Open)1 recommendation
Shaz Rajput
Software Architect at Walmart.com
Sukaina has a natural talent to bring out a positive/friendly environment in any situation and works well with different personality types. She is easily approachable and always willing to help. She has the tenacity to pursue difficult tasks to…View
Additional Info
Personal Details
Birthday    January 30
Organizations
Additional Organizations
Academy of Management Academy of International Business Strategic Management Society Association of Strategic Planning Association of Corporate Growth Corporate Directors Forum MIT Forum Harvard Business Society The Indus Entrepreneur (TiE) San Diego Ventures Group (SDVG) Stanford Technology Ventures Program (STVP)
Specialties:Research, analysis, due diligence, financial analysis, economic development consulting
Our PPM including financial forecasts were circulated to our entire experienced advisory team for review and input – http://www.calstockexchange.com/team-cal-x/

Disclaimer Regarding the Term “Companies” Used in our Materials: In our accelerator and incubator terminology “companies” often refers to a new innovation being developed with full intention to form a separate spin out company IN-THE-FUTURE when the innovation has completed mentored incubated development into a full fledged organization with a web site, slide deck, basic business plan, board, team and has gotten some marketplace traction, including independent funding or revenues, to commence operations as a stand alone independent separately legally formed corporation. We DO NOT file “companies” to become independent separate legal entity “C or S corporations” until they are at an advanced stage of development and are deemed by our board or lead management to be ready to survive on their own. All early stage seed “companies” within the accelerator/incubator share the same accelerator or venture fund checking account, accounts payable and receivable clerks, accountants, lawyers, web site developers, support staff, consultants, advisory board, conference rooms, offices, telephone systems, internet wifi accounts and even management personnel until they are advanced enough with a dedicated focused team in place with strength enough to be pushed out of the next to fly on their own and feed themselves (get their own independent funding). We avoid filing to early stage “companies” to be independent stand alone legally registered ” C or S corporations” until they are truly deemed to be fully ready to be self reliant. This avoids un-necessary legal fees associated with city, county, state and federal filings. So until they are legally spun out as a separate entity these “companies” or “innovations” are officially product innovation development teams or projects under the Cal-X Stars Business Accelerator, Inc. or Leonhardt Vineyards LLC DBA Leonhardt Ventures umbrella organizations. Our Private Placement Memorandum for Cal-X Stars Business Accelerator, Inc. published on the password protected sitewww.healthiosxchange.com (reserved for verified accredited investors only) provides clear guidance on which “companies” have moved from being internal or external innovations under development into full fledged separate stand alone legal entities.

Accuracy of Information Disclaimer: Representations and warranties – although we fully believe that our executive summaries, newsletters, websites and other written materials and videos accurately represent a true and accurate general high level picture of our activities, history and progress – which is developing about 15 early stage un-proven cardiovascular life innovations and 15 early stage startup social good impact innovations (including new media social good projects) in an accelerator/incubator – we acknowledge that working with a very small core staff covering many thousands of pages of written materials across over 40 web sites with over 4000 sub-pages that we are highly prone to small errors, outdated materials and a certain level on inaccuracy and inconsistencies even while fully striving for the utmost accuracy. Across the 30+ innovations and over 2000 working partnerships being developed there are changes and events that occur almost daily. We do our best to keep all websites and published materials fully up to date but recognize and make clear it is nearly impossible for our small staff to keep all materials on all web sites 100% up to date despite our best efforts to do so. Investors have the advantage with us that our small staff operates with a very low overhead but the offset disadvantage is that we do not have on hand the staffing to handle all the constant updates and proofreads needed to keep thousands of pages of materials up to date and 100% accurate 100% of the time. If you have ANY direct question about any published item of material interest to you – JUST ASK for clarification by emailing direct Howard Leonhardt at hleonhardt@aol.com or calling our office DIRECT LINE at 310 310 2534. We will strive to provide a clarification or update to you promptly.

Our framework for driving growth and creating shareholder value = FOCUS on the right things.

Asli Gozoren

Background & Experience

We offer two opportunities with us:

Bruce Methven

Background & Experience

Risks & Warnings

ALL Cal-X Stars Business Accelerator, Inc. investors must verify their accredited status via Crowdentials, EarlyIQ or Healthiosxchange

Proposed Use of Proceeds $15 million 506D Part C Shares Offering 2018

Leonhardt‘s Launchpads by Cal-X Stars Business Accelerator, Inc.

Brief quick elevator pitches for startups in 2017 … – Leonhardt Ventures

Accelerator and innovation laboratory focused on cardiovascular technologies and social good impact enterprises

About CalxStars

Contact Details

Follow us